RxDoctor Payments Data

Peter Lenchur, MD

Cardiovascular Disease · Roselle, NJNPI 1457335309

Payments from drug & device makers

$11,558in general payments, 2019–2025

Across 485 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
  • AstraZeneca$854
  • Johnson & Johnson$812
  • Abbott$765
  • Boehringer Ingelheim$666
  • Amgen$645
  • plus $5K from 37 others

What the payments were for

  • Speaking & faculty fees$1,50013%
  • Food & beverage$10,03687%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,558 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$214,446
Medicare patients
925
Services billed
3,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban417$412,533
EntrestoSacubitril/Valsartan189$202,645
XareltoRivaroxaban151$145,717
Repatha SureclickEvolocumab81$83,495
JardianceEmpagliflozin83$68,708
FarxigaDapagliflozin Propanediol39$46,965
Praluent PenAlirocumab15$17,122
BrilintaTicagrelor12$13,483
EdarbyclorAzilsartan Med/Chlorthalidone27$13,352
Metoprolol Succinate957$12,471
Atorvastatin Calcium1,071$12,178
MultaqDronedarone Hcl13$9,175
DiovanValsartan17$7,873
VerquvoVericiguat11$7,460
VascepaIcosapent Ethyl13$5,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$433$412,533417 claims
NovartisEntresto, Diovan$600$210,517206 claims
Johnson & JohnsonXarelto$812$145,717151 claims
Boehringer IngelheimJardiance$666$68,70883 claims
AstraZenecaFarxiga, Brilinta$854$60,44751 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$14$13,35227 claims
Sanofi-aventis U.S. LLCMultaq$275$9,17513 claims
MerckVerquvo$620$7,46011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Roselle

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →